Clarithromycin inhibits LPS-induced NF-κB (p65) DNA binding in vivo, alleviates DSS-induced colitis in murine models, and suppresses TNF-induced NF-κB (p65) nuclear localization in human ileal organoids, further study is necessary to confirm its effects in patients (Lloyd et al., 2020). The gene discussed is NFKB1; the disease is colitis.